Perha Pharmaceuticals

Perha Pharmaceuticals is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors and developing them up to proof-of-concept in man. Perha Pharma focuses its research on two main diseases: cognitive disorders associated with Down syndrome (DS) and Alzheimers disease (AD), and hearing loss (HL) induced by ototoxic products. The first proof-of-concept in man should be achieved in both pathologies through niche indications: cognitive deficits in DS and hearing loss induced by cis-platin or aminoglycoside antibiotics. Perha Pharma was co-founded in April 2019 by Dr Laurent MEIJER, Chairman & CSO, former distinguished Director of Research at the...

Medicinal chemistry,biotechnology,biology,kinase inhibitors,drug development,down syndrome,hearing loss,and adpkd

Perha pharmaceuticals operates in the Biotechnology research industry.

Perha pharmaceuticals's revenue is 11m - 100m

Perha pharmaceuticals has 11 - 50 employees.